Orchestra BioMed (OBIO) news
Recent news
Orchestra Biomed Holdings Inc: Piper Sandler raises target price to $12 from $10
Piper Sandler has raised its price target for Orchestra BioMed Holdings Inc (OBIO) to $12 from $10, reflecting a positive reassessment of the company’s near-term clinical and operational catalysts. The firm maintains a "Buy" rating on the stock, citing progress in advancing key therapeutic programs…
AInvest Wire · Oct 1, 2026Orchestra Biomed - Primary endpoint data to be submitted for presentation at cardiovascular conference in Q2 2027
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has outlined a timeline for the submission of primary endpoint data from its BACKBEAT Trial, which is evaluating AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. The company, in collaboration with Medtronic,…
AInvest Wire · Oct 1, 2026Orchestra Biomed exceeds full enrollment target in the Backbeat global pivotal trial of Avim therapy
AInvest Wire · Oct 1, 2026Orchestra Biomed receives $6.1 million milestone payment from acquisition of Vivasure by Haemonetics
AInvest Wire · Sep 15, 2026Orchestra Biomed Holdings Inc: BTIG raises to buy from neutral
AInvest Wire · Sep 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.